The Future of Anti-Amyloid Trials
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
The termination of many clinical trials of amyloid-targeting therapies for the treatment of Alzheimer's disease (AD) has had a major impact on the AD clinical research enterprise. However, positive signals in recent studies have reinvigorated support for the amyloid hypothesis and amyloid-targeting strategies. In December 2019, the EU-US Clinical Trials on Alzheimer's Disease (CTAD) Task Force met to share learnings from these studies in order to inform future trials and promote the development of effective AD treatments. Critical factors that have emerged in studies of anti-amyloid monoclonal antibody therapies include developing a better understanding of the specific amyloid species targeted by different antibodies, advancing our insight into the mechanism by which those antibodies may reduce pathology, implementing more comprehensive repertoires of biomarkers into trials, and identifying appropriate doses. Studies suggest that Amyloid-Related Imaging Abnormalities - effusion type (ARIA-E) are a manageable safety concern and that caution should be exercised before terminating studies based on interim analyses. The Task Force concluded that opportunities for developing effective treatments include developing new biomarkers, intervening in early stages of disease, and use of combination therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
Self-citationThe antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · cited 1×
“The Task Force discussed five anti-amyloid monoclonal ant ibody therapies current ly in clinical development: aducanumab (7), BAN2401 (6), gantenerumab (8), solanezumab (9–13) , and donanemab.”
BackgroundSelf-citationPhase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
Self-citationTrial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., Hager, K., Andreasen, N., Scarpini, E., Liu-Seifert, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705971 · Cited by 1,049
Self-citationSperling, R. A., Jack, C. R., Black, S. E., Frosch, M. P., Greenberg, S. M., Hyman, B. T., Scheltens, P., Carrillo, M. C., Thies, W., Bednar, M. M., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.05.2351 · Cited by 857 · cited 1×
“The inc idence of amyloid-re la ted imaging abnormalities – effusion type (ARIA-E) associated with anti-Aβ antibody treatment has been a substantial concern in the development of these therapies (18).”
BackgroundSelf-citationAnti-Amyloid-β Monoclonal Antibodies for Alzheimer’s Disease: Pitfalls and Promise
van Dyck, C. H. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.08.010 · Cited by 568
A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
for the SCarlet RoAD Investigators, Ostrowitzki, S., Lasser, R. A., Dorflinger, E., Scheltens, P., Barkhof, F., Nikolcheva, T., Ashford, E., Retout, S., Hofmann, C., et al. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0318-y · Cited by 567 · cited 3×
“5 that fast progressors showed a greater exposuredependent slowing of clinical and cognitive decline with treatment (8).”
BackgroundTesting the Right Target and Right Drug at the Right Stage
Sperling, R. A., Jack, C. R., & Aisen, P. S. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002609 · Cited by 550
Self-citationRandomized trial of verubecestat for prodromal Alzheimer's disease
Egan, M. F., Kost, J., Voss, T., Mukai, Y., Aisen, P. S., Cummings, J. L., Tariot, P. N., Vellas, B., van Dyck, C. H., Boada, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812840 · Cited by 545
Self-citationPhase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients
Siemers, E. R., Sundell, K. L., Carlson, C., Case, M., Sethuraman, G., Liu‐Seifert, H., Dowsett, S. A., Pontecorvo, M. J., Dean, R. A., & Demattos, R. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.06.1893 · Cited by 370
Research works printed but not linked: 12
- Wessels, 2019, Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials, JAMA Neurol
- Cummings, 2018, ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease, Neurology, 90, e1889, 10.1212/WNL.0000000000005550 · DOI · Paper page
- Farlow, 2012, Safety and biomarker effects of solanezumab in patients with Alzheimer's disease, Alzheimers Dement, 8, 261, 10.1016/j.jalz.2011.09.224 · DOI · Paper page
- Willis, 2018, Central pharmacodynamic activity of solanezumab in mild Alzheimer's disease dementia, Alzheimers Dement (N Y), 4, 652, 10.1016/j.trci.2018.10.001 · DOI · Paper page
- Doody, 2020, The role of futility analyses in AD clinical trials, J Prev Alz Dis, 7
- Aisen, 2019, Editorial: Failure After Failure. What Next in AD Drug Development?, J Prev Alzheimers Dis, 6, 150, 10.14283/jpad.2019.23 · DOI
- Zetterberg, 2019, Blood-based molecular biomarkers for Alzheimer's disease, Molecular Brain, 12, 26, 10.1186/s13041-019-0448-1 · DOI · Paper page
- Gauthier, 2019, Combination Therapy for Alzheimer's Disease: Perspectives of the EU/US CTAD Task Force, J Prev Alzheimers Dis, 6, 164, 10.14283/jpad.2019.12 · DOI · Paper page
- Cummings, 2019, Anti-Tau Trials for Alzheimer's Disease: A Report from the EU/US/CTAD Task Force, J Prev Alzheimers Dis, 6, 157, 10.14283/jpad.2019.14 · DOI · Paper page
- Harrison, 2019, Tau deposition is associated with functional isolation of the hippocampus in aging, Nat Commun, 10, 4900, 10.1038/s41467-019-12921-z · DOI · Paper page
- Chen, 2019, Learnings about the complexity of extracellular tau aid development of a blood-based screen for Alzheimer's disease, Alzheimers Dement, 15, 487, 10.1016/j.jalz.2018.09.010 · DOI · Paper page
- Aisen, 2018, What Have We Learned from Expedition III and EPOCH Trials? Perspective of the CTAD Task Force, J Prev Alzheimers Dis, 5, 171, 10.14283/jpad.2018.23 · DOI
Cited by
Nguyen, P. H., Ramamoorthy, A., Sahoo, B. R., Zheng, J., Faller, P., Straub, J. E., Dominguez, L., Shea, J.-E., Dokholyan, N. V., De Simone, A., et al. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01122 · Cited by 678
Orr, M., Gonzales, M., Garbarino, V., Kautz, T., Palavicini, J., Lopez-Cruzan, M., Dehkordi, S. K., Mathews, J., Zare, H., Xu, P., et al. (2023) · doi:10.21203/rs.3.rs-2809973/v1 · Cited by 319
Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial
Gonzales, M. M., Garbarino, V. R., Kautz, T. F., Palavicini, J. P., Lopez-Cruzan, M., Dehkordi, S. K., Mathews, J. J., Zare, H., Xu, P., Zhang, B., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02543-w · Cited by 334
Quantification of amyloid PET for future clinical use: a state-of-the-art review
Pemberton, H. G., Collij, L. E., Heeman, F., Bollack, A., Shekari, M., Salvadó, G., Alves, I. L., Garcia, D. V., Battle, M., Buckley, C., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05784-y · Cited by 226
Park, S. H., Baik, K., Jeon, S., Chang, W. S., Ye, B. S., & Chang, J. W. (2021) · Translational Neurodegeneration · doi:10.1186/s40035-021-00269-8 · Cited by 95
Metadata
- Authors
- Aisen, P. S., Cummings, J., Doody, R., Kramer, L., Salloway, S., Selkoe, D. J., Sims, J., Sperling, R. A., & Vellas, B.
- Venue
- The Journal of Prevention of Alzheimer's Disease
- Publisher
- Elsevier BV
- Published
- 2020-06
- Volume
- 7
- Issue
- 3
- Pages
- 146-151
- ISSN
- 2274-5807 (ISSN-L)
- OpenAlex
- W3026315764
- Cited by
- 59
- References
- 17
- FWCI
- 5.41
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Future of Anti-Amyloid Trials. https://app.cochat.ai/papers/10.14283/jpad.2020.24
- The paper
- Aisen, P. S., Cummings, J., Doody, R., Kramer, L., Salloway, S., Selkoe, D. J., Sims, J., Sperling, R. A., & Vellas, B. (2020). The Future of Anti-Amyloid Trials. The Journal of Prevention of Alzheimer's Disease. https://doi.org/10.14283/jpad.2020.24
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.